header image

Healthcare Professionals

Bruce Cheson, M.D.
Professor of Medicine, Georgetown University Hospital

Speaks on the value of TREANDA®

"The non-Hodgkin's lymphomas are a group of at least thirty different diseases. And, we tend to classify them into the indolent, the aggressive, and the very aggressive.  The indolent can be slow growing, but unfortunately, while they respond to treatment, they are incurable.

Most patients will eventually progress after initial treatment or are refractory to initial treatment; new drugs are needed.  One of the most promising of these new drugs is bendamustine, or TREANDA, which achieves responses in many patients with non-Hodgkin's lymphomas."

Please remember individual results may vary.

TREANDA Prescribing Information >>